Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded by Zacks Investment Research to Hold

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people […]

Related Keywords

,Geode Capital Management ,Eledon Pharmaceuticals ,Zacks Investment Research ,Novus Therapeutics Inc ,Renaissance Technologies ,Vanguard Group Inc ,Cantor Fitzgerald ,Eledon Pharmaceuticals Get Rating ,Millennium Management ,Eledon Pharmaceuticals Inc ,Get Rating ,Pharmaceuticals Inc ,Capital Management ,Street Corp ,Vanguard Group ,Nasdaq Eldn ,Heldn ,Medical ,Upgrade ,